

Carlo Tumscitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7569481/publications.pdf>

Version: 2024-02-01

31
papers

2,055
citations

516710

16
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

2500
citing authors

#	ARTICLE	IF	CITATIONS
1	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Circulation</i> , 2012, 125, 2015-2026.	1.6	640
2	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , The, 2018, 392, 940-949.	13.7	555
3	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 20-28.	2.9	124
4	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	2.8	101
5	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	2.2	93
6	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 804-811.	2.7	66
7	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 506-512.	2.8	58
8	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2017, 167, 17.	3.9	56
9	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 36-50.	2.9	47
10	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study). <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 555-562.	1.7	40
11	Acute myocardial infarction and large coronary thrombosis in a patient with COVID-19. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 272-277.	1.7	37
12	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. <i>Platelets</i> , 2016, 27, 484-487.	2.3	32
13	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 313-320.	2.6	25
14	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 602-611.	1.7	20
15	Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1375-1377.	2.9	18
16	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	1.9	18
17	Comparison of quantitative flow ratio, Pd/Pa and diastolic hyperemia-free ratio versus fractional flow reserve in non-culprit lesion of patients with non-ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1057-1065.	1.7	17
18	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 211-223.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Seven french radial artery access for PCI: A prospective single-center experience. International Journal of Cardiology, 2014, 176, 1074-1075.	1.7	14
20	Optical coherence tomography evaluation of overlapping everolimus-eluting bioresorbable vascular scaffold implantation guided by enhanced stent visualization system. International Journal of Cardiology, 2015, 182, 1-3.	1.7	13
21	Enhanced stent visualization systems during PCI: A case series and review of literature. Journal of Cardiology Cases, 2015, 12, 1-5.	0.5	12
22	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	2.5	12
23	Snuffbox approach for balloon aortic valvuloplasty: A case series. Catheterization and Cardiovascular Interventions, 2021, 97, E743-E747.	1.7	10
24	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	2.2	10
25	Balloon aortic valvuloplasty for urgent treatment of severe aortic stenosis during coronavirus disease 2019 pandemic: a case report. ESC Heart Failure, 2020, 7, 4348-4352.	3.1	7
26	Contemporary balloon aortic valvuloplasty: Changing indications and refined technique. Catheterization and Cardiovascular Interventions, 2021, 97, E1033-E1042.	1.7	7
27	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 82-89.	1.6	7
28	TCT-478 Results of the Italian Multicenter Register of the Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty (Softly II). Journal of the American College of Cardiology, 2019, 74, B473.	2.8	1
29	COMPARISON OF VERAPAMIL VERSUS HEPARIN THERAPY ON PROCEDURAL SUCCESS DURING TRANSRADIAL CORONARY PROCEDURES (VERMUT STUDY). Journal of the American College of Cardiology, 2017, 69, 969.	2.8	0
30	TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial. Journal of the American College of Cardiology, 2018, 72, B49.	2.8	0
31	No-Reflow Complicating Chronic Total Occlusion Coronary Revascularization. Journal of Invasive Cardiology, 2020, 32, 58-63.	0.4	0